The Phase III study FIND-CKD ( NCT05047263) — investigating the efficacy and safety of KERENDIA ® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic ...

Bayer announces finerenone meets primary endpoint in pivotal phase III FIND-CKD study in patients with non-diabetic chronic kidney disease: Berlin Tuesday, March 17, 2026, 15:00 H ...

BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression.

Severe hypothyroidism is associated with a high burden of systolic/diastolic ventricular dysfunction and myocardial deformation abnormalities.

Estrogen may help protect against hypertension in premenopause, a new study suggests, raising further questions about the role that hormone therapy may play in cardiovascular health later in life.

Commonly prescribed heart medications, including statins and diuretics, do not negatively affect the survival of ...

Keros Therapeutics, Inc. ('Keros” or the 'Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on ...

The Ace CNG 2.0 Bi-Fuel is designed for low running and maintenance costs. Image Source : Special Arrangements New Delhi: Tata Motors Commercial Vehicles has expanded its iconic Ace range of small ...

A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has revealed how a tryptophan-rich allosteric communication network regulates ...

The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification.

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).